16
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Green Renal Replacement Therapy: Caring for the Environment

      Submit here before July 31, 2024

      About Blood Purification: 3.0 Impact Factor I 5.6 CiteScore I 0.83 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Executive Summary: Clinical Practice Guideline for Autosomal Dominant Polycystic Kidney Disease in China

      guideline

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease, with a prevalence of 1/2,500–1/1,000, and it affects 1.25 million people in China. ADPKD is responsible for nearly 5% of end-stage renal disease cases, which leads to a major burden on public health. In 2016, the Chinese working group developed guidelines for the diagnosis and treatment of ADPKD, which promoted the clinical management of ADPKD in China. In the last 3 years, Chinese clinicians have deepened their understanding and standardized the management of ADPKD, and several basic and clinical studies on ADPKD have been conducted. In combination with international guidelines and research results, the working group updated the ADPKD guidelines in China. This guideline includes 5 chapters: introduction, diagnosis, kidney disease progression monitoring, treatment, and family planning. We highlight the main recommendations and suggestions of the ADPKD guidelines in this summary.

          Related collections

          Author and article information

          Journal
          KDD
          KDD
          10.1159/issn.2296-9357
          Kidney Diseases
          S. Karger AG
          2296-9381
          2296-9357
          2020
          May 2020
          19 March 2020
          : 6
          : 3
          : 144-149
          Affiliations
          [_a] aDepartment of Nephrology, Changzheng Hospital, Second Military Medical University, Shanghai, China
          [_b] bDepartment of Nephrology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
          [_c] cDepartment of Nephrology, The Third Affiliated Hospital, Hebei Medical University, Shijiazhuang, China
          [_d] dDepartment of Nephrology, Peking Union Medical College Hospital, Beijing, China
          [_e] eDepartment of Nephrology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, China
          [_f] fDepartment of Nephrology, The First Affiliated Hospital, Anhui Medical University, Hefei, China
          [_g] gDepartment of Nephrology, Qilu Hospital, Shandong University, Jinan, China
          [_h] hDepartment of Nephrology, Guizhou Provincial People’s Hospital, Gui Yang, China
          [_i] iDepartment of Nephrology, Second Xiangya Hospital, Central South University, Changsha, China
          [_j] jDepartment of Nephrology, 900 Hospital of the Joint Logistics Team, PLA, Fuzhou General Clinical Medical College of Fujian Medical University, Fuzhou, China
          [_k] kDepartment of Nephrology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
          [_l] lDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, China
          [_m] mDepartment of Nephrology, The Third Affiliated Hospital, Peking University, Peking, China
          [_n] nSichuan Academy of Medical Science and Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science, Chengdu, China
          Author notes
          *Chang-Lin Mei or Cheng Xue, Kidney Institute, Department of Nephrology, Changzheng Hospital, 415 Fengyang Rd., Shanghai 200003 (China), changlinmei@smmu.edu.cn or xuecheng@smmu.edu.cn
          Author information
          https://orcid.org/0000-0002-4132-9406
          https://orcid.org/0000-0003-3565-8024
          https://orcid.org/0000-0003-1970-9979
          Article
          506288 Kidney Dis 2020;6:144–149
          10.1159/000506288
          32523956
          70dc828d-5561-474e-9f87-f72a0a902f4c
          © 2020 The Author(s) Published by S. Karger AG, Basel

          This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          : 09 January 2020
          : 30 January 2020
          Page count
          Tables: 2, Pages: 6
          Categories
          Guidelines

          Cardiovascular Medicine,Nephrology
          Diagnosis,Gene,End-stage renal disease,Treatment,Autosomal dominant polycystic kidney disease

          Comments

          Comment on this article